Add‐on treatment with vinpocetine reduces seizure frequency and improves comorbidities in patients with loss‐of‐function γ‐aminobutyric acid type A receptor variants
Epilepsia · 2026
DOI: 10.1002/epi.70310 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Epilepsia, 2026. Verfasst von Cathrine E Gjerulfsen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epilepsy Genetics and Personalized Medicine, Danish Epilepsy Centre, Filadelfia (member of European Reference Network EpiCARE), Dianalu…. Hauptthemen laut MEDLINE: Vinca Alkaloids, Receptors, GABA-A, Seizures, Anticonvulsants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
The semisynthetic compound vinpocetine has gained attention as a potential precision medicine for developmental and epileptic encephalopathies caused by loss‐of‐function (LoF) variants in γ‐aminobutyric acid type A (GABA A ) receptor genes. As a positive allosteric modulator of GABA A receptors, case reports suggest that vinpocetine can reduce epileptiform activity and seizure frequency, while improving cognitive function in patients with GABA A receptor‐related epilepsies. Here, we extend these observations with a retrospective observational study evaluating the response to vinpocetine in an additional seven patients.
Methods
Patients initiated treatment with vinpocetine between 2018 and 2025 at the Danish Epilepsy Centre or abroad. Clinical data were collected from medical records, seizure diaries, and neuropsychological assessments. The modulatory efficacy of vinpocetine was investigated using electrophysiological studies.
Results
Nine patients harboring eight GABA A receptor LoF variants were given add‐on vinpocetine treatment. Electrophysiological analyses confirmed dose‐dependent positive modulation by vinpocetine across tested variants. Six patients with a median age of 15.5 years (range = 6–29) continued treatment for a median of 24 months (range = 12–90), whereas three discontinued due to adverse effects (AEs) or lack of efficacy. The patients' level of function ranged from normal to moderate intellectual disability, psychiatric comorbidities, and behavioral disturbances. Four patients initiated vinpocetine due to uncontrolled seizures. One became seizure‐free, and two experienced a 50%–55% reduction. Electroencephalograms demonstrated improved spike–wave indexes in four patients. Six showed improvement in nonseizure factors, and caregivers reported reduced aggressivity and better vocabulary in one. Vinpocetine was well tolerated, with only mild and reversible AEs reported. Significance Adjunctive vinpocetine shows promise as a targeted therapy for patients with GABA A receptor LoF variants, decreasing seizure frequency and positively impacting nonseizure factors, with only mild AEs reported. Vinpocetine may be a safe and effective therapy for patients with GABA A receptor‐related epilepsies, which should be investigated further in future N ‐of‐1 trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epilepsy Genetics and Personalized Medicine, Danish Epilepsy Centre, Filadelfia (member of European Reference Network EpiCARE), Dianalund, Denmark.
- Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.
- Brain and Mind Centre, School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
- Department of Child Neurology, Danish Epilepsy Centre, Dianalund, Denmark.
- Department of Interdisciplinary Health Research, Danish Epilepsy Centre, Dianalund, Denmark.
- Department of Psychology, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.
ORCID-Profile: Cathrine E Gjerulfsen, Elena Gardella, Allan Bayat, Cecilie Johannessen Landmark, Orrin Devinsky, Guido Rubboli, Rikke S Møller
Zitieren
APA
Gjerulfsen, C. E., Liao, V. W. Y., Mieszczanek, T. S., Jakobsen, A. V., Gardella, E., Olofsson, K., Nikanorova, M., Bayat, A., Ortiz, S., Weckhuysen, S., Landmark, C. J., Devinsky, O., Chebib, M., Ahring, P. K., Rubboli, G., & Møller, R. S. (2026). Add‐on treatment with vinpocetine reduces seizure frequency and improves comorbidities in patients with loss‐of‐function γ‐aminobutyric acid type A receptor variants. Epilepsia. https://doi.org/10.1002/epi.70310
Vancouver
Gjerulfsen CE, Liao VWY, Mieszczanek TS, Jakobsen AV, Gardella E, Olofsson K, et al. Add‐on treatment with vinpocetine reduces seizure frequency and improves comorbidities in patients with loss‐of‐function γ‐aminobutyric acid type A receptor variants. Epilepsia. 2026. doi:10.1002/epi.70310
BibTeX
@article{Gjerulfsen2026,
author = {Gjerulfsen, Cathrine E and Liao, Vivian W Y and Mieszczanek, Tomasz S and Jakobsen, Anne V and Gardella, Elena and Olofsson, Kern and Nikanorova, Marina and Bayat, Allan and Ortiz, Sebastian and Weckhuysen, Sarah and Landmark, Cecilie Johannessen and Devinsky, Orrin and Chebib, Mary and Ahring, Philip K and Rubboli, Guido and Møller, Rikke S},
title = {Add‐on treatment with vinpocetine reduces seizure frequency and improves comorbidities in patients with loss‐of‐function γ‐aminobutyric acid type A receptor variants},
journal = {Epilepsia},
year = {2026},
doi = {10.1002/epi.70310}
}
EUVIMED